NEW YORK, Sept. 11 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH). The full 60-page report can be found at http://www.crystalra.com.
Tapestry Pharmaceuticals, Inc. ("Tapestry" or "the Company") is a biopharmaceutical company developing New Chemical Entities that may be effective in treating a broad spectrum of cancers. The Company's lead compound, TPI 287, is a novel, proprietary, third-generation taxane. Although taxanes have been used as cancer therapies for many years, treatment with these drugs is often plagued by undesirable effects, the most notable of which is the emergence of multi-drug resistance (MDR). To address this, Tapestry is developing TPI 287, which has shown the ability to overcome MDR in preclinical experiments.
In particular, TPI 287 targets MDR-1 (the primary mechanism responsible for tumor resistance to taxanes). TPI 287 has also shown efficacy in preclinical studies in a broad range of cell lines versus comparator drugs. Furthermore, in animal models, TPI 287 has shown greater oral bioavailability than paclitaxel, an approved taxane.
The Company filed an Investigational New Drug (IND) application for TPI 287 with the U.S. Food and Drug Administration (FDA) and commenced two Phase 1 studies, each with a different dosing regimen. The first Phase 1 study, which began in January 2005, employed a Q7D X3 regimen (dosing every seven days for three weeks), while the second Phase 1 study, which started in January 2006, used a Q21D (dosing every 21 days) regimen. The objectives of these Phase 1 trials were to determine the maximum tolerated dose (MTD) to be used in Phase 2 studies as well as to determine the safety, anti-tumor, and pharmacokinetic and pharmacodynamic profiles of TPI 287. In October 2006, the Company reached the MTD of its second Phase 1 trial. The Company is headquartered in Boulder, Colorado, with offices in New Jersey and New York.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of forty seven thousand five hundred dollars for its services in creating this report, for updates, and for printing costs
Forward-Looking Safe Harbor Statement
Statements in this news release regarding the potential effectiveness of TPI 287 in treating a broad spectrum of cancers and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from the results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties, and other factors include risks that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of protocols, negotiations with regulatory agencies, or other factors, and that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that the Company is blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that the Company is limited in its ability to obtain, maintain, and enforce its own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional information on factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-K, 10-Q, and any other forms filed by the Company with the Securities and Exchange Commission.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.
|SOURCE Crystal Research Associates, LLC|
Copyright©2007 PR Newswire.
All rights reserved